DOCSLIB.ORG

Integrating Treatment for Autism Spectrum Disorders Through the Life Cycle

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Integrating Treatment for Autism Spectrum Disorders Through the Life Cycle Integrating Treatment for Autism Spectrum Disorders Through the Life Cycle Robert L Hendren, DO Professor of Psychiatry and Behavioral Science Idaho Autism Summit November 2, 2019 Faculty Disclosure • Grants — Curemark, Roche, Otsuka • Advisory Board — Curemark, BioMarin, Janssen, Axial Biotherapeutics • Honoraria/Royalties: Oxford University Press, Taylor & Francis • Dr. Hendren does intend to discuss the use of off- label/unapproved use of drugs Learning Objectives • Identify successes and challenges in the developmental progression through the life cycle for people with developmental disabilities and their families • Identify and effectively treat comorbid medical, emotional and behavioral symptoms associated with autism spectrum disorders (ASD) • Consider integrating biomedical treatments for ASD including conventional psychotropic medication and what has been referred to as CAM/CIM into a comprehensive program. 2010 1 in 68; 2014 1 in 59 CDC Prevalence of Autism • Possible explanations include – Diagnostic expansion and substitution – Better reporting – Increased recognition – Increasing acceptability – Immigration for services – Environmental toxins – Infectious and immune vulnerability – Epigenetic processes Rutter M. Acta Pediatr. 2005;94(1):2-15. Centers for Disease Control and Prevention. Autism Spectrum Disorders. www.cdc.gov/ncbddd/autism. Accessed June 16, 2015. Hagerman R, Hendren RL (Eds). Treatment of Neurodevelopmental Disorders: Targeting Neurobiological Mechanisms. Oxford University Press; 2014. ASD Genetic Etiology (Levels 1 & 2) • Multiple genes: NRXN12q, 7q11.23, 15q11-13, 16p11.2, SHANK 3, 2, NLGN4, MTHFR 677>T, SEMA5A, 2Q22.1, GRIN2B, 5P14.1, CDH9, 10, FRX, PTEN • Identical twins: 60% to 90% – Fraternal twins: 0% to 36% – Siblings: 4% to 19% • Clear genetic etiology accounts for 25% of autism cases • Hundreds of genetic mutations, some de novo, lead to many ways to develop and treat autism • Is Precision Medicine Possible? Weiss KM, Issues Science and Technology in 2017 Levy D, et al. Neuron. 2011;70(5):886-897. Miles JH. Genet Med. 2011;13(4):278-294. Lossifov I, et al. Neuron. 2012;74(2):285-299. Murdoch JD, et al. Curr Opin Genet Dev. 2013;23(3):310-315. ASD and Environmental Risk • Documented: prenatal or early postnatal exposure to viral infections (rubella), valproic acid, thalidomide (Level 1) • Proposed: influence of mercury, lead, environmental toxins, vaccines, lack of vitamin D (Levels 3 & 4) • Parental age (older paternal and maternal; differences) (Level 1) • Maternal metabolic conditions (Level 2) • Influenza or fever during pregnancy (Level 2) • Environmental pollution (Level 2) Herbert MR. Curr Opin Neurol. 2010;23(2):103-110. Landrigan PJ. Curr Opin Pediatr. 2010;22(2):219- 225. Sandin S, et al. Mol Psychiatry. 2015;[Epub ahead of print]. Shelton JF, et al. Autism Res. 2010;3(1):30-39. Frans EM, et al. JAMA Psychiatry. 2013;70(5):516-521. Krakowiak P, et al. Pediatrics. 2012;129(5)e1121-e1128. Zerbo O, et al. J Autism Dev Disord. 2013;43(1):25-33. Schuler K, Institute for Agriculture and Trade Policy. www.iatp.org/files/2013_12_04_Autism_KS.pdf. Accessed June 16, 2015. Model for Autism Etiology • First hit – Genetic neurodevelopmental vulnerability • Second hit – Environmental “stressor” and interaction between the two • Third hit – Restricted development Translating from “Terroir”: Model Epigenetic Layer to Targeted Treatment Level 4 Level 3 Level 2 Level 1 Hagerman R, Hendren RL (Eds). Treatment of Neurodevelopmental Disorders: Targeting Neurobiological Mechanisms. Oxford University Press; 2014. Gene-Environment Interactions and Epigenetic Processes (Level 2) Immune abnormalities/ Oxidative stress Disturbed methylation inflammation Mitochondrial Free fatty acid Excitatory/inhibitory dysfunction metabolism imbalance Hormonal effects Microglia/Astrocytes Microbiome Goines P, et al. Curr Opin Neurol. 2010;23(2):111-117. James SJ, et al. Am J Clin Nutr. 2009;89(1):425-430. Frye RE, et al. Pediatr Res. 2011;69(5 Pt 2):41R-47R. Manji H, et al. Nat Rev Neurosci. 2012;13(5):293-307. Bell JG, et al. Br J Nutr. 2010;103(8):1160-1167. Rubenstein JL. Curr Opin Neurol. 2010;23(2):118-123. Harony H, et al. Neurosignals. 2010;18(2):82- 97. Cunningham CL. J Neurosci. 2013;33(10):4216-4233. Autism Through the Life Cycle Brain Growth and Development • Parental history and early developmental experiences also exert effects through epigenetic information not contained in the DNA sequence, which cause changes in gene expression – methylation and chromatin patterning – Histone acetylation – noncoding RNAs and mitochondria • Transgenerational epigenetic effects interact with conditions at conception to program the developmental trajectory of the embryo and fetus, ultimately affecting the lifetime health of the child Wells et al, 2016; Lane M, et al. Science. 2014;345(6198):756-760. Brain Growth and Development • We searched the MEDLINE database for studies published between January 1, 2005 and July 1, 2018 for perinatal risk factors and autism, risk factors such as infections, medications, and environmental factors including non-chemical stressors, chemical and nutritional factors. Then, we searched for interventions that may improve neurodevelopmental outcome including nutritional supplements during pregnancy, breastfeeding, and postpartum stress reduction. • Our review, in agreement with other reviews, supports the possibility that interventions to normalize or mitigate these processes, particularly in the preconception or perinatal period, could lead to resilience and health in the developing and newborn child. Cheng…Hendren, Medical Hypothesis, 127 (2019) 26-33 Hertz-Picciotto et al, 2018, Wang et al, 2017, Getahun et al., 2017, Hisle-Gorman et al., 2018 Pregnancy Autism Risk (Grade B Mod) • Maternal Infection and Inflammation (congenital rubella) • Environmental Toxicants (methylmercury, PCBs, Toluene, Arsenic) • Air Pollution • Pesticides • Bisphenols and Phthalates • Valproic Acid • Thalidomide • SSRIs • Acetaminophen • Heavy Metals Atladottir et al., 2010; Ornoy et al, 2016; Muzhe & Chou, 2017; Eskenazi et al, 2008; Kondolot et al, 2016; Christensen et al. 2013; Croen et al, 2011; Bourkhris et al, 2016; Avella-Garcia CB et al, 2016; Kern 2016 Can Autism be Prevented? (Grade C Mod) • Folic Acid and multivitamin Supplements before and during pregnancy associated with reduced risk of ASD (45,300 children; P<.001) • Omega -3 Polyunsaturated Fatty Acid • Vitamin D • Antioxidants • Iron • Choline/phosphatidylcholine • One practice minimized toxicant exposure; maximized breastfeeding; probiotics, nutritional counseling; limited antibiotics; minimized acetaminophen – Out of 294 general pediatric patients followed since 2005 there were 0 new cases of autism Levine SZ et al., 2018; Suren et al., 2013; Morgese & Trabace, 2016; Stubbs et al., 2016; Zhang et al, 2015; Schmidt et al., 2014; Ross et al, 2016; Mumper E. North American Journal of Medicine and Science. 2013;6(3):134-144 P2i – Preconception to Infancy • Goal is to establish a program that reduces miscarriages and helps ensure infants a healthy start in life • www.ForumP2i.com • University of Georgia Center for Excellence • Be Fruitful: The Essential Guide to Maximizing Fertility and Giving Birth to a Healthy Child, Victoria Maizes, MD, Scribner, NY, 2013 Early Intervention The majority of research and clinical programs are targeted at younger children where neurodevelopmental processes are more plastic Parental Concerns, Provider Response, and Timeliness of ASD Dx • Compared with children with ID/DD, children with ASD were younger when parents first had concerns and first discussed those concerns with a provider • Compared with parents of children with ID/DD, parents of children with ASD were less likely to receive proactive responses to their concerns and more likely to receive reassuring/passive responses • Among children with ASD, those with more proactive provider responses to concerns had shorter delays in ASD diagnosis compared with those with passive/reassuring provider responses • Although parents of children with ASD have early concerns, delays in diagnosis are common, particularly when providers’ responses are reassuring or passive, highlighting the need for targeted improvements in primary care ID/DD = intellectual disorder/developmental disorder. Zuckerman KE, et al. J Pediatr. 2015;166(6):1431-1439.e1. Later Intervention Is late adolescence and young adulthood too late to intervene? Development in ASD in Adolescence (Levels 2 & 3) • Microstructure of the thalamus, a key sensory and motor brain area, appears to develop differently in individuals with autism spectrum disorder with differences narrowing with age. • PEERS social skills treatment improves particular aspects of emotional, behavioral, and social functioning that may be necessary for developing and maintaining quality peer relationships and remediating social isolation in adolescents with ASD. Ecker C, et al. Lancet Neurol. 2015;S1474-4422(15)00050-2. Lainhart JE. Curr Opin Psychiatry. 2015;28(2):76-82. McLaughlin K et al, Autism Res. 2017; N Lordo D, J Autism Dev Disord. 2017 47(1):203-214. Postsecondary Employment Experiences among Young Adults with ASD • Approximately one-half (53.4%) of young adults with ASD had ever worked for pay outside the home since leaving high school, the lowest rate among disability groups • Young adults with an ASD earned an average of $8.10/hour, significantly lower than average wages for young adults in the comparison groups, and held jobs
Load more

Recommended publications
  • Issue 111 Special Needs
    Issue 111 INSIDE THIS ISSUE Bureau of Community and Special Needs Health Systems From the Division Direc- Child Care Licensing Division tor ................................... 1 www.michigan.gov/michildcare Social Emotional Skills .. 2 (866) 685-0006 Working with Children with Attention Deficit Disorder ......................... 3 Autism 101 ...................... 4 Children with Sensory Processing Disorder ....... 5 From My World to Your Classroom or Home ....... 8 Developmentally Appro- priate Behaviors and Ex- pectations ....................... 9 ADA……….………………..14 FROM THE DIVISION DIRECTOR 2018 is coming to a close very rapidly from Child Care Licensing’s point of view. You have been constantly emailed, sent list serve notices, called or mailed information about the changes we were implementing in 2018. Thanks for your patience as we all went through all of the changes! Background check implementation journey in 2018: • Since March 28th until today we have processed over 77,900 fingerprints of staff, household members and licensees in Michigan. Remember we had no idea how many people worked in child care when we started. The state has paid for almost $3 million dollars of background checks for the child care provid- ers. • The updated PA116 of 1973 finally passed in December of 2017 and went into effect March 28, 2018. We are processing the rule changes currently. • Our in-person trainings were carried out to thousands of child care staff across the entire state over the past 12 months • Our backlog of fingerprints were at over 16,000 just a couple of months ago and today we are down to less than 190. This reduction will allow hiring to be processed much faster for providers employers.
    [Show full text]
  • Optumrx Brand Pipeline Forecast
    RxOutlook® 1st Quarter 2019 OptumRx brand pipeline forecast Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status release date drug drug 2019 Possible launch date Ophthalmological DS-300 DS-300 Eton undisclosed SC Filed NDA 2019 unknown N disease anti-sclerostin Evenity romosozumab Amgen Osteoporosis SC Filed NDA 2/2019 Y N monoclonal antibody tetrahydrofolate iclaprim iclaprim Motif Bio Bacterial infections IV Filed NDA 2/13/2019 Y Y dehydrogenase inhibitor tazarotene/ IDP-118 Valeant retinoid/ corticosteroid Psoriasis TOP Filed NDA 2/15/2019 N N halobetasol adenosine deaminase Mavenclad cladribine Merck/ Teva resistant Multiple sclerosis PO Filed NDA 2/15/2019 Y N deoxyadenosine analog Lotemax Gel loteprednol Valeant corticosteroid Ocular inflammation OP Filed NDA 2/25/2019 N N Nex Gen etabonate turoctocog alfa glyco-PEGylated factor NN-7088 Novo Nordisk Hemophilia IV/SC Filed BLA 2/27/2019 Y N pegol VIII derivative selective sphingosine-1 BAF-312 siponimod Novartis phosphate receptor Multiple sclerosis PO Filed NDA 3/1/2019 Y N agonist midazolam midazolam UCB benzodiazepine Seizures Intranasal Filed NDA 3/1/2019 N Y (USL-261) XeriSol glucagon Xeris glucagon analog Diabetes mellitus SC Filed NDA 3/1/2019 N N Glucagon optum.com/optumrx 1 RxOutlook® 1st Quarter 2019 Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status release date drug drug dopamine receptor JZP-507 sodium oxybate Jazz Narcolepsy
    [Show full text]
  • Pharmacological Management of Autism Spectrum Disorders
    Pharmacological Management of Autism Spectrum Disorders Lightin the Way 2018 David Ermer Md Pharmacotherapy common in Autism Spectrum iIlnesses (ASDs) ◼ 45% of children and adolescents with ASDs treated with psychotropic medications ◼ 75% of adults with ASDs treated with psychotropic medications Research into Psychotropic Medications in ASD’s is Relatively New ◼ Before 2006 there were no FDA approved medications for use in Autism ◼ With the increased incidence of ASDs being reported, there is increased interest from the pharmaceutical industry Treatment Strategies for Pharmacologic Intervention ◼ Pharmacologic treatments are available and significantly beneficial ◼ Educational and behavioral supports are the mainstays of treatment ◼ It is essential to integrate behavioral and pharmacologic treatments Realistic Expectations Must be Set ◼ Expectation that symptoms remit more quickly with pharmacologic treatment over behavioral treatments ◼ Expectation that response will be more complete with pharmacologic treatments ◼ “magic bullets” Must Optimize Environment ◼ Evaluate school setting ◼ Work with caregivers on home environment ◼ Pharmacologic strategies ineffective in unsupportive and inadequate environments Parental Collaboration is Essential ◼ Monitor patient and provide information to provider ◼ Administer medication ◼ Observe side effects ◼ Note emotional and behavioral effects ◼ Collaborate their information with school Focus on Symptom Clusters ◼ Most of the core symptoms are likely to remain ◼ Must focus on specific measurable symptoms
    [Show full text]
  • Regressive Autism: a Study in Early Developmental Patterns Rebekah L
    Southern Illinois University Carbondale OpenSIUC Research Papers Graduate School 5-2014 Regressive Autism: A Study In Early Developmental Patterns Rebekah L. Brewer Southern Illinois University Carbondale, [email protected] Follow this and additional works at: http://opensiuc.lib.siu.edu/gs_rp Recommended Citation Brewer, Rebekah L., "Regressive Autism: A Study In Early Developmental Patterns" (2014). Research Papers. Paper 465. http://opensiuc.lib.siu.edu/gs_rp/465 This Article is brought to you for free and open access by the Graduate School at OpenSIUC. It has been accepted for inclusion in Research Papers by an authorized administrator of OpenSIUC. For more information, please contact [email protected]. i REGRESSIVE AUTISM: A STUDY IN EARLY DEVELOPMENTAL PATTERNS by Rebekah L. Brewer B.S., Southern Illinois University, 2012 A Research Paper Submitted in Partial Fulfillment of the Requirements for the M.S. Communication Disorders & Science. Rehabilitation Institution In the Graduate School Southern Illinois University Carbondale May 2014 RESEARCH PAPER APPROVAL REGRESSIVE AUTISM: A STUDY IN EARLY DEVELOPMENTAL PATTERNS By Rebekah L. Brewer A Research Paper Submitted in Partial Fulfillment of the Requirements for the Degree of Master of Science in the field of Communication Disorders & Science Approved by: Valerie Boyer, Ph.D., CCC-SLP Kirsten Schaper, M.S., CCC-SLP Graduate School Southern Illinois University Carbondale November 11, 2013 TABLE OF CONTENTS CONTENT PAGE Introduction ...................................................................................................
    [Show full text]
  • Medical Comorbidities in Autism Spectrum Disorders
    TA-ESPA-ATP PAPER 2014 1st draft_Layout 1 21/07/2014 19:21 Page 1 Medical Comorbidities in Autism Spectrum Disorders A Primer for Health Care Professionals and Policy Makers Second Edition: July 2014 Prepared by: l Treating Autism l ESPA Research l Autism Treatment Plus TA-ESPA-ATP PAPER 2014 1st draft_Layout 1 21/07/2014 19:21 Page 2 Treating Autism , a charity run entirely by volunteers, provides information and support to families and individuals affected by autism with the aim of improving their quality of life. Registered Charity: www.treatingautism.co.uk No. 1113628, Limited Company Registered in England: No. 5594787. ESPA Research is a not-for-profit subsidiary of ESPA (Education and Services for People with Autism) dedicated to undertaking high-quality research into autism and related conditions all for the public benefit. www.espa-research.org.uk ESPA Research Ltd. Company registration: 6862992. ESPA Registered Charity No. 1037868 | Company No. 2909953 Autism Treatment Plus, dedicated to helping individuals with autism reach optimal health and learning, provides access to diagnostic, medical and behavioural services. www.autismtreatment.org.uk. Limited company registered in England: No. 08623707. © Treating Autism Publications, 2014 Second edition, published July 2014. (First edition published March 2013). All rights reserved. Reproduction of this report, in its entirety and unaltered, by photocopying or electronic means for noncommercial purposes is permitted. Otherwise, no part of this report may be reproduced, adapted, stored in a retrieval system or transmitted by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of Treating Autism Publications. ISBN: 978-0-9575787-2-2 A pdf version of this publication is available from the Treating Autism website www.treatingautism.co.uk.
    [Show full text]
  • Horizon Scanning Status Report, Volume 2
    PCORI Health Care Horizon Scanning System Volume 2, Issue 3 Horizon Scanning Status Report September 2020 Prepared for: Patient-Centered Outcomes Research Institute 1828 L St., NW, Suite 900 Washington, DC 20036 Contract No. MSA-HORIZSCAN-ECRI-ENG-2018.7.12 Prepared by: ECRI Institute 5200 Butler Pike Plymouth Meeting, PA 19462 Investigators: Randy Hulshizer, MA, MS Damian Carlson, MS Christian Cuevas, PhD Andrea Druga, PA-C Marcus Lynch, PhD, MBA Misha Mehta, MS Prital Patel, MPH Brian Wilkinson, MA Donna Beales, MLIS Jennifer De Lurio, MS Eloise DeHaan, BS Eileen Erinoff, MSLIS Cassia Hulshizer, AS Madison Kimball, MS Maria Middleton, MPH Diane Robertson, BA Melinda Rossi, BA Kelley Tipton, MPH Rosemary Walker, MLIS Andrew Furman, MD, MMM, FACEP Statement of Funding and Purpose This report incorporates data collected during implementation of the Patient-Centered Outcomes Research Institute (PCORI) Health Care Horizon Scanning System, operated by ECRI under contract to PCORI, Washington, DC (Contract No. MSA-HORIZSCAN-ECRI-ENG-2018.7.12). The findings and conclusions in this document are those of the authors, who are responsible for its content. No statement in this report should be construed as an official position of PCORI. An intervention that potentially meets inclusion criteria might not appear in this report simply because the Horizon Scanning System has not yet detected it or it does not yet meet inclusion criteria outlined in the PCORI Health Care Horizon Scanning System: Horizon Scanning Protocol and Operations Manual. Inclusion or absence of interventions in the horizon scanning reports will change over time as new information is collected; therefore, inclusion or absence should not be construed as either an endorsement or rejection of specific interventions.
    [Show full text]
  • How Different Is Early-Onset Childhood Disintegrative Disorder from Autistic Disorder with Speech Loss?*
    Open Journal of Psychiatry, 2013, 3, 39-45 OJPsych http://dx.doi.org/10.4236/ojpsych.2013.32A007 Published Online April 2013 (http://www.scirp.org/journal/ojpsych/) How different is early-onset childhood disintegrative * disorder from autistic disorder with speech loss? Hiroshi Kurita1,2#, Kanna Inoue3 1Department of Child Psychiatry, Zenkoku Ryoiku Sodan Center, Tokyo, Japan 2Department of Mental Health, Graduate School of Medicine, Tokyo University, Tokyo, Japan 3Department of Child Psychiatry, Nerima Welfare Center for Handicapped Persons, Tokyo, Japan Email: #[email protected] Received 27 February 2013; revised 30 March 2013; accepted 9 April 2013 Copyright © 2013 Hiroshi Kurita, Kanna Inoue. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Diagnosis; Regression To examine the difference between early-onset (< age 3) childhood disintegrative disorder (CDD) and au- 1. INTRODUCTION tistic disorder with speech loss (ADSL), 8 children Childhood disintegrative disorder (CDD) originates from with early-onset CDD (mean age = 7.6 years, SD = 3.8; Dementia infantilis first reported by Heller [1] in 1908 in 6 males) were compared with 92 age and gender-ratio six infants who had displayed profound mental regres- comparable children with ADSL (mean age = 6.8 sion during the third and fourth years of life. CDD is a years, SD = 4.1; 70 males) on 24 variables not directly subtype of pervasive developmental disorders (PDDs) in related to the key features of CDD (regression after DSM-IV [2] and ICD-10 [3], using similar diagnostic normal development for at least the first 2 years after criteria.
    [Show full text]
  • Is There a 'Regressive Phenotype' of Autism Spectrum Disorder Associated with the Measles-Mumps-Rubella Vaccine?
    Journal of Autism and Developmental Disorders, Vol. 36, No. 3, April 2006 (Ó 2006) DOI 10.1007/s10803-005-0070-1 Published Online: April 28, 2006 Is There a ‘Regressive Phenotype’ of Autism Spectrum Disorder Associated with the Measles-Mumps-Rubella Vaccine? A CPEA Study Jennifer Richler,1 Rhiannon Luyster,1 Susan Risi,1 Wan-Ling Hsu,1 Geraldine Dawson,2 Raphael Bernier,2 Michelle Dunn,3 Susan Hepburn,4 Susan L. Hyman,5 William M. McMahon,6 Julie Goudie-Nice,6 Nancy Minshew,7 Sally Rogers,8 Marian Sigman,9 M. Anne Spence,10 Wendy A. Goldberg,10 Helen Tager-Flusberg,11 Fred R. Volkmar,12 and Catherine Lord13 A multi-site study of 351 children with Autism Spectrum Disorders (ASD) and 31 typically developing children used caregiver interviews to describe the children’s early acquisition and loss of social-communication milestones. For the majority of children with ASD who had experienced a regression, pre-loss development was clearly atypical. Children who had lost skills also showed slightly poorer outcomes in verbal IQ and social reciprocity, a later mean age of onset of autistic symptoms, and more gastrointestinal symptoms than children with ASD and no regression. There was no evidence that onset of autistic symptoms or of regression was related to measles-mumps-rubella vaccination. The implications of these findings for the existence of a ‘regressive phenotype’ of ASD are discussed. KEY WORDS: Autism spectrum disorder; language development; regression; Autism Diagnostic Interview - Revised (ADI-R); measles-mumps-rubella (MMR) vaccine; gastrointestinal disorders. While most children with Autism Spectrum Dis- orders (ASD) are described as showing developmental differences from birth or early in infancy, a substantial 1 University of Michigan, Ann Arbor, USA.
    [Show full text]
  • Lääkeaineiden Yleisnimet (INN-Nimet) 21.6.2021
    Lääkealan turvallisuus- ja kehittämiskeskus Säkerhets- och utvecklingscentret för läkemedelsområdet Finnish Medicines Agency Lääkeaineiden yleisnimet (INN-nimet) 21.6.
    [Show full text]
  • National Institute of Mental Health (NIMH) Autism Research Program
    NIMH Autism Research Program Discovering the Causes & Cures of Autism and Conducting Meaningful “Until Then” Research Susan E. Swedo, M.D. Pediatrics & Developmental Neuroscience Branch National Institute of Mental Health NIH Intramural Research Program Finding the Causes & Cures for Autism Environmental Genetically Trigger Susceptible Host Developmentally Sensitive Period Abnormal Brain Development, Symptoms Structure &/or of Autism Function NIMH Autism Research Program • Multi-disciplinary Clinical Research Team – M.D.’s – Pediatrics, child psychiatry, neurology – Ph.D.’s – Developmental & clinical psychologists – Other professionals – Social work, biostatistics • Support staff and Trainees – Administrative and support staff – Clinical and research fellows – Physicians, psychologists, speech and language pathologist – Post-baccalaureate IRTAs who plan to attend medical school or graduate school in 1 – 2 years You are Our Office here To Cedar Lane Collaborative Relationships • Within NIMH – CBDB: Emotional processing – CHP: DTI and Structural MRI scans – LBC: Social cognition; executive functions; fMRI (resting state) – LBN: Animal models – LNT: Proteomics/metabolomics – MAP: Co-morbid disorders; treatment trials; biostatistics – MIB: Magnetic resonance spectroscopy • Within NIH – NCI: Neuroinflammatory markers – NHGRI: Specific genetic syndromes (e.g. SMS) – NIAID: Lymphocyte phenotyping and viral titers – NICHD: Clinical genetics (WAGR, SLO); CTDB; stem cell models (from skin fibroblasts) – NIDCR: Dysmorphology – NINDS: Electroencephalography
    [Show full text]
  • Autism with and Without Regression: a Two-Year Prospective Longitudinal Study in Two Population-Derived Swedish Cohorts
    Journal of Autism and Developmental Disorders https://doi.org/10.1007/s10803-018-03871-4 ORIGINALPAPER Autism With and Without Regression: A Two-Year Prospective Longitudinal Study in Two Population-Derived Swedish Cohorts Lucy Thompson1,2 · Christopher Gillberg1,2 · Sara Landberg1 · Anne‑Katrin Kantzer1 · Carmela Miniscalco1 · Martina Barnevik Olsson1,3 · Mats A. Eriksson1,4 · Elisabeth Fernell1 © The Author(s) 2019 Abstract Two community-based cohorts of children with autism spectrum disorder, examined using similar assessment protocols, were pooled (n = 301) and subdivided according to history of regression. Those with regression (n = 62), 20.5% of the com- bined cohort, were contrasted with those without regression (n = 241) at first assessment (age range 19–60 months) and at 2-year follow-up on a range of measures. The regression group was significantly more functionally impaired, with regard to intellectual function (p < .001), language development (p < .001), and to severity of autism (p < .01) at both T1 and T2. Only 14 (23.3%) had a clearly identified underlying etiology [24 (18.6%) in the non-regressive group]. There were no significant differences between those who had regressed ‘from normal’ and those who had regressed ‘from low’ functioning. Keywords Autism · ASD · Regressive autism · Non-regressive autism · Intellectual developmental disorder · Developmental language disorder Introduction (i.e., rely on existing diagnoses within a population (e.g., Baird et al. 2008). The few systematic studies that have been Many children with autism spectrum disorder (ASD) published seem to indicate that regression in autism is (a) (American Psychiatric Association 2013) have shown mild not uncommon, but the relative prevalence is not known, and or marked developmental problems from early childhood (b) associated with high rated of intellectual developmental (Coleman and Gillberg 2012).
    [Show full text]
  • Does Theory of Mind Performance Differ in Children with Earlyonset and Regressive Autism?
    Developmental Science 15:1 (2012), pp 25–34 DOI: 10.1111/j.1467-7687.2011.01094.x PAPER Does theory of mind performance differ in children with early-onset and regressive autism? Nicole L. Matthews,1 Wendy A. Goldberg,1 Angela F. Lukowski,1 Kathryn Osann,2 Maryam M. Abdullah,1 Agnes R. Ly,1 Kara Thorsen1 and M. Anne Spence2 1. Department of Psychology and Social Behavior, University of California, Irvine, USA 2. Department of Pediatrics, University of California, Irvine, USA Abstract A deficit in theory of mind (ToM), or the ability to infer the mental states of others, has been implicated as one of the major characteristics of Autism Spectrum Disorder (ASD); however, little attention has been devoted to possible differences in ToM ability within ASD. The current study examined ToM performance in children with early-onset autism and regressive autism in comparison to typically developing children. Results indicated that children in the regressive autism group performed significantly better than the early-onset autism group on the non-verbal appearance–reality task. Additionally, Fisher’s exact tests indicated a pattern of lowest scores in the early-onset group and highest scores in the typically developing group, whereas the regressive autism group tended to score in between the early-onset and typically developing groups. The apparent heterogeneity in ToM performance within ASD could account for the lack of universality in ToM ability found in previous studies. Introduction developed in order to address such criticisms. For example, investigators have creatively examined the Autism spectrum disorders (ASD) are characterized by appearance–reality distinction by asking children to restricted repetitive behaviors and qualitative impair- choose between objects by pointing rather than using ments in social interaction and communication (Lord, expressive language to give an answer.
    [Show full text]